Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Clin Mol Hepatol. 2022 Apr;28(2):269-272. doi: 10.3350/cmh.2022.0040. Epub 2022 Feb 15.

Authors

Affiliations

¹ Department of Dermatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
² Department of Dermatology, Kurume University School of Medicine, Kurume, Japan.
³ Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
⁴ Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.

No abstract available

Keywords: Interleukin-17; Liver fibrosis; Metabolic diseases; Non-alcoholic fatty liver disease; Psoriasis.

Publication types

Letter

MeSH terms

Humans
Interleukin-17
Liver
Liver Cirrhosis / complications
Non-alcoholic Fatty Liver Disease* / complications
Non-alcoholic Fatty Liver Disease* / drug therapy
Psoriasis* / complications
Psoriasis* / drug therapy

Substances

Interleukin-17